 |
December 4, 2006
Life Plus LLC forms strategic alliance with Washington, D.C.-based consulting firmWEST LAFAYETTE, Ind. and WASHINGTON, D.C., December 4, 2006 — West Lafayette-based Life Plus LLC announced today it has entered into an exclusive collaborative partnership with Washington, D.C.-based The Acta Group LLC to provide expertise on Asia's biotechnology-related product registration process.
The Acta Group is a consulting affiliate of Bergeson & Campbell, P.C., a leading Washington, D.C., law firm that assists with product approval and regulation, product defense and associated business issues for a large number of clients in several countries with chemical control laws.
As a Purdue Research Park-based company that specializes in regulatory approval support services (i.e. compiling supporting toxicology data packages, including expert statements, literature reviews and risk assessments), Life Plus will collaborate with The Acta Group to control the spiraling costs and inefficiencies experienced by clients seeking regulatory approval to commercialize new chemical technologies, as well as products of biotechnology, nanotechnology and medical devices.
"Life Plus' affiliation with several Chinese toxicology labs provides an advantage to clients by improving the speed of mandatory testing in Chinese labs and by reducing the testing costs, which can exceed several hundred thousand dollars," said Mark Cisneros, Ph.D., president and CEO of Life Plus, which has been successful in its efforts to gain regulatory approvals for chemical and medical device technologies attempting to enter the Chinese marketplace.
"Bergeson & Campbell's and its affiliate's chemical regulatory practice is best-in-class and broadly focused, and this collaboration with Acta will allow Life Plus to offer services in new regulatory areas — such as agrochemicals and nanotechnologies — to our expanding client base," Cisneros said.
"We take a multidisciplinary approach in assisting our clients, partnering with toxicological, chemical, engineering, economic, and other experts on individual matters as necessary to achieve results effectively and efficiently," said Lynn L. Bergeson, president of The Acta Group and a founding member of Bergeson & Campbell, P.C. "We chose Life Plus because the company has an outstanding reputation in delivering a full-service offering to clients interested in commercializing new chemical technologies in the Asian marketplace."
With headquarters at Purdue Research Park in West Lafayette, Ind., and operations in Beijing, China, Life Plus LLC (https://www.lifeplustox.com) offers regulatory guidance and trade development support to firms throughout the world. The company's customer-focused philosophy has generated valuable results for clients, including the first successful navigation of a new substance notification through the Chinese's new chemical control law. Purdue Research Park is one of the largest business/science parks in the country and home to companies developing technologies discovered at the Birck Nanotechnology Center, the cornerstone for Purdue University's $300 million Discovery Park. Within Purdue Research Park, 140 businesses, of which more than 90 are high-tech, employ more than 2,900 people.
The Acta Group LLC (https://www.actagroup.com) is a consulting firm established to control the spiraling costs and inefficiencies encountered by clients seeking approvals to market agricultural and industrial chemicals, products of biotechnology and nanotechnology, and FDA-regulated products. The Acta Group manages products from concept to approval, utilizing the skills and experience of professionals who have worked in the specific product areas in government and industry. The Acta Group's U.K. affiliate is The Acta Group EU, Ltd., which focuses on REACH, biocides, nanotechnology, and related chemical product approval programs and EU Directives.
Bergeson & Campbell, P.C. (https://www.lawbc.com) is an AV-rated (highest ranked) Washington, D.C., law firm focusing on industrial, agricultural, and specialty chemical and medical device, product approval and regulation, product defense, and associated business issues. Bergeson & Campbell, P.C.'s clients are involved in many businesses, including basic, specialty, and agricultural and antimicrobial chemicals; biotechnology, nanotechnology, and emerging transformative technologies; pharmaceuticals, medical devices, and diagnostic products; fibers; paints and coatings; printing and publishing; plastic products; and hazardous waste remediation. The firm represents and counsels individuals, business entities, trade associations and industry coalitions.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
|
